AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003Proactive Investors • 03/17/26
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor DayProactive Investors • 03/10/26
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor DayGlobeNewsWire • 03/10/26
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trialProactive Investors • 03/06/26
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical UpdateGlobeNewsWire • 03/06/26
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backingProactive Investors • 03/03/26
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder TranscriptSeeking Alpha • 02/27/26
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trialProactive Investors • 02/26/26
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety DisorderGlobeNewsWire • 02/26/26
AtaiBeckley seen as key beneficiary of Spravato's strong growth: JefferiesProactive Investors • 01/21/26
AtaiBeckley shares clinical and preclinical data at ACNP Annual MeetingProactive Investors • 01/16/26
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic PresentationGlobeNewsWire • 01/16/26
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/26